StemCell Therapy

Advance Market Analyticsreleased the research report of Global Internet of Nano Things Market, offers a detailed overview of the factors influencing the global business scope.Global Internet of Nano Things Market research report shows the latest market insights with upcoming trends and breakdown of the products and services.The report provides key statistics on the market status, size, share, growth factors of the Global Internet of Nano Things.This Report covers the emerging players data, including: competitive situation, sales, revenue and global market share of top manufacturers are Honeywell International Inc. (United States), Intel Corporation (United States), Microsoft (United States), Apex Probes Ltd. (United Kingdom), Qualcomm Technologies, Inc. (United States), IBM (United States), Applied Nanodetectors Ltd. (United Kingdom), Siemens AG (Germany), Juniper Networks, Inc. (United States), Eutelsat (France), AT&T (United States), Huawei Technologies Co., Ltd. (China) and Kineis (France)

Free Sample Report + All Related Graphs & Charts @ https://www.advancemarketanalytics.com/sample-report/38796-global-internet-of-nano-things-market

The internet of nano things (IoNT) is an integrated system of miniaturized devices particularly nanosensors that are used to transfer data over the network connectivity. The various nanotechnologies integrated together into an IoNT system are used for a wide number of applications specifically a smart industry will use IoNT devices to monitor the temperature, humidity, and other environmental conditions. This technology is also widely used in the biomedical and healthcare sector for genetic engineering, health monitoring, etc. Many automobiles connected with those nanosensors or IoNT can help exchange data such as spatial information for improving the safety and accuracy of the automobile assistance systems.

Market Trend

Market Drivers

Opportunities

Restraints

Challenges

The Global Internet of Nano Thingsis segmented by following Product Types:

Application (Health Monitoring, Genetic Engineering, Environment Monitoring, Nuclear, Biological, and Chemical (NBC) Defenses, Food and Water Quality Control, Others), Components (Nano Nodes, Nano Routers, Nano Micro Interface Device, Gateway), Industry Verticals (Biomedical & Healthcare Industry, Transportation & Logistics Industry, Media & Entertainment Industry, Defense & Aerospace Industry, Manufacturing Industry, Energy & Utilities Industry, Retail Industry, Others)

Region Included are: North America, Europe, Asia Pacific, Oceania, South America, Middle East & Africa

Country Level Break-Up: United States, Canada, Mexico, Brazil, Argentina, Colombia, Chile, South Africa, Nigeria, Tunisia, Morocco, Germany, United Kingdom (UK), the Netherlands, Spain, Italy, Belgium, Austria, Turkey, Russia, France, Poland, Israel, United Arab Emirates, Qatar, Saudi Arabia, China, Japan, Taiwan, South Korea, Singapore, India, Australia and New Zealand etc.

Enquire for customization in Report @:https://www.advancemarketanalytics.com/enquiry-before-buy/38796-global-internet-of-nano-things-market

Strategic Points Covered in Table of Content of Global Internet of Nano Things Market:

Chapter 1: Introduction, market driving force product Objective of Study and Research Scope the Global Internet of Nano Things market

Chapter 2: Exclusive Summary the basic information of the Global Internet of Nano Things Market.

Chapter 3: Displayingthe Market Dynamics- Drivers, Trends and Challenges of the Global Internet of Nano Things

Chapter 4: Presenting the Global Internet of Nano Things Market Factor Analysis Porters Five Forces, Supply/Value Chain, PESTEL analysis, Market Entropy, Patent/Trademark Analysis.

Chapter 5: Displaying the by Type, End User and Region 2013-2018

Chapter 6: Evaluating the leading manufacturers of the Global Internet of Nano Things market which consists of its Competitive Landscape, Peer Group Analysis, BCG Matrix & Company Profile

Chapter 7: To evaluate the market by segments, by countries and by manufacturers with revenue share and sales by key countries in these various regions.

Chapter 8 & 9: Displaying the Appendix, Methodology and Data Source

Finally, Global Internet of Nano Things Market is a valuable source of guidance for individuals and companies.

Data Sources & Methodology

The primary sources involves the industry experts from the Global Internet of Nano Things Market including the management organizations, processing organizations, analytics service providers of the industrys value chain. All primary sources were interviewed to gather and authenticate qualitative & quantitative information and determine the future prospects.

In the extensive primary research process undertaken for this study, the primary sources Postal Surveys, telephone, Online & Face-to-Face Survey were considered to obtain and verify both qualitative and quantitative aspects of this research study. When it comes to secondary sources Companys Annual reports, press Releases, Websites, Investor Presentation, Conference Call transcripts, Webinar, Journals, Regulators, National Customs and Industry Associations were given primary weight-age.

Get More Information: https://www.advancemarketanalytics.com/reports/38796-global-internet-of-nano-things-market

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

About Author:

Advance Market Analytics is Global leaders of Market Research Industry provides the quantified B2B research to Fortune 500 companies on high growth emerging opportunities which will impact more than 80% of worldwide companies revenues.

Our Analyst is tracking high growth study with detailed statistical and in-depth analysis of market trends & dynamics that provide a complete overview of the industry. We follow an extensive research methodology coupled with critical insights related industry factors and market forces to generate the best value for our clients. We Provides reliable primary and secondary data sources, our analysts and consultants derive informative and usable data suited for our clients business needs. The research study enable clients to meet varied market objectives a from global footprint expansion to supply chain optimization and from competitor profiling to M&As.

Contact Us:

Craig Francis (PR & Marketing Manager)AMA Research & Media LLPUnit No. 429, Parsonage Road Edison, NJNew Jersey USA 08837Phone: +1 (206) 317 1218[emailprotected]

Connect with us athttps://www.linkedin.com/company/advance-market-analyticshttps://www.facebook.com/AMA-Research-Media-LLP-344722399585916https://twitter.com/amareport

Read the rest here:
Internet of Nano Things Market Sees Slowest Growth on Consumption Slump - Latest Herald

Ongoing advancements in cancer research continue to lead to the introduction of newer and better treatment options including drug therapies. The provision of newer drugs and treatments is expected to improve the diagnostic and treatment rate for triple-negative breast cancer.

Some of the recent clinical efforts are being targeted at the molecular level characterization of triple-negative breast cancer across emerging therapeutic targets such as epigenetic proteins, PARP1, androgen receptors, receptor and non-receptor tyrosine kinases, and immune checkpoints.

Report Highlights:

Get Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/14305

Company Profiles

These initiatives are anticipated to boost revenue growth of the triple-negative breast cancer treatment market. In a new research study, Persistence Market Research estimates the globaltriple-negative breast cancer treatment marketrevenue to cross US$ 720 Mn by 2026 from an estimated valuation of just under US$ 505 Mn in 2018. This is indicative of a CAGR of 4.7% during the period 2018 to 2026.

Get To Know Methodology of Report @ https://www.persistencemarketresearch.com/methodology/14305

Development of generics is another key opportunity area in the triple-negative breast cancer treatment market. With the rapidly expanding number of cancer cases across the world, there is a need for effective cancer management, including the provision of better and more efficient drugs.

Developing economies are faced with challenges on several fronts including paucity of funds and lack of proper treatment options, calling for more innovative approaches to affordable healthcare. The availability of biosimilars and affordable generic anti-cancer drugs in developing regions is expected to significantly reduce the burden of cancer care.

A projected cost reduction to the tune of more than 30% 40% and extended use of generic drugs is expected to reduce overall cancer treatment costs, thereby increasing the treatment rate for triple-negative breast cancer. This is further anticipated to create lucrative growth opportunities in the global triple-negative breast cancer treatment market.

Advances in Cancer Treatment and Introduction of Innovative Cancer Treatment Drugs to Boost Revenue Growth of the Triple-Negative Breast Cancer Treatment Market

Breast cancer is one of the most common types of cancer in women, and over the years, pharmaceutical and life sciences companies have been conducting advanced research and development activities to devise newer treatment options and drugs to treat breast cancer.

Several new drug formulations are currently in the pipeline in different stages of clinical development and this is expected to bode well for the triple-negative breast cancer treatment market. Innovation in oncology therapeutics has shifted focus towards an outcome based approach to cancer care, with an increasing emphasis on combination drugs and newer therapeutic modalities.

This is further likely to put the global triple-negative breast cancer treatment market on a positive growth trajectory in the coming years.

Access Full Report @ https://www.persistencemarketresearch.com/checkout/14305

Combination Therapy and Advancements in Nano Medicine Research Trending the Triple-Negative Breast Cancer Treatment Market

One of the biggest trends being observed in the global market for triple-negative breast cancer treatment is the shift towards combination therapy. Companies in the global triple-negative breast cancer treatment market are conducting clinical trials for combination therapies by collaborating with other players in the market.

Combination therapies are the latest innovation in the field of oncology and the combination of therapeutic drugs with chemotherapy is said to be an effective protocol for the treatment of triple-negative breast cancer.

Another huge trend in the triple-negative breast cancer treatment market is the emergence of nanotechnology as an efficient tool in the clinical management of critical diseases such as triple-negative breast cancer. It has been observed that the combination of gold nanoparticles and folic acid results in higher cell entry rate in both in-vitro and in-vivo models, indicative of the fact that folate receptors are effective targeted therapies for the treatment of triple-negative breast cancer.

Nanoparticles facilitate systematic and efficient delivery of drugs and agents to the site of the tumor. Advanced R&D in nanotechnology and nano medicine is one of the top trends likely to impact the global triple-negative breast cancer treatment market in the years to come.

Read the original here:
Triple Negative Breast Cancer Treatment Market to Grow at Stellar CAGR Double In% During the Forecast Period 2026 - Cole of Duty

Analysis Report on Nanomedicine Market

A report on global Nanomedicine market has hit stands. This study is based on different aspects like segments, growth rate, revenue, leading players, regions, and forecast. The overall market is getting bigger at an increased pace due to the invention of the new dynamism, which is making rapid progress.

The given report is an excellent research study specially compiled to provide latest insights into critical aspects of the Global Nanomedicine Market.

Request Sample Report @https://www.mrrse.com/sample/3117?source=atm

Some key points of Nanomedicine Market research report:

Strategic Developments: The custom analysis gives the key strategic developments of the market, comprising R&D, new product launch, growth rate, collaborations, partnerships, joint ventures, and regional growth of the leading competitors operating in the market on a global and regional scale.

Market Features: The report comprises market features, capacity, capacity utilization rate, revenue, price, gross, production, production rate, consumption, import, export, supply, demand, cost, market share, CAGR, and gross margin. In addition, the report offers a comprehensive study of the market dynamics and their latest trends, along with market segments and sub-segments.

Analytical Tools: The Global Nanomedicine Market report includes the accurately studied and assessed data of the key industry players and their scope in the market by means of a number of analytical tools. The analytical tools such as Porters five forces analysis, feasibility study, and many other market research tools have been used to analyze the growth of the key players operating in the market.

COVID-19 Impact on Nanomedicine Market

Adapting to the recent novel COVID-19 pandemic, the impact of the COVID-19 pandemic on the global Nanomedicine market is included in the present report. The influence of the novel coronavirus pandemic on the growth of the Nanomedicine market is analyzed and depicted in the report.

The global Nanomedicine market segment by manufacturers include

market dynamics section of this report analyzes the impact of drivers and restraints on the global nanomedicine market. The impact of these drivers and restraints on the global nanomedicine market provides a view on the market growth during the course of the forecast period. Increasing research activities to improve the drug efficacy coupled with increasing government support are considered to be some of the major driving factors in this report. Moreover, few significant opportunities for the existing and new market players are detailed in this report.

Porters five forces analysis provides insights on the intensity of competition which can aid in decision making for investments in the global nanomedicine market. The market attractiveness section of this report provides a graphical representation for attractiveness of the nanomedicine market in four major regions North America, Europe, Asia-Pacific and Rest of the World, based on the market size, growth rate and industrial environment in respective regions, in 2012.

The global nanomedicine market is segmented on the basis of application and geography and the market size for each of these segments, in terms of USD billion, is provided in this report for the period 2011 2019. Market forecast for this applications and geographies is provided for the period 2013 2019, considering 2012 as the base year.

Based on the type of applications, the global nanomedicine market is segmented into neurological, cardiovascular, oncology, anti-inflammatory, anti-infective and other applications. Other applications include dental, hematology, orthopedic, kidney diseases, ophthalmology, and other therapeutic and diagnostic applications of nanomedicines. Nanoparticle based medications are available globally, which are aimed at providing higher bioavilability and hence improving the efficacy of drug. There have been increasing research activities in the nanomedicine filed for neurology, cardiovascular and oncology applications to overcome the barriers in efficient drug delivery to the target site. Moreover, the global nanomedicine market is also estimated and analyzed on the basis of geographic regions such as North America, Europe, Asia-Pacific and Rest of the World. This section describes the nanomedicine support activities and products in respective regions, thus determining the market dynamics in these regions.

The report also provides a few recommendations for the exisitng as well as new players to increase their market share in the global nanomedicine market. Some of the key players of this market include GE Healthcare, Mallinckrodt plc, Nanosphere Inc., Pfizer Inc., Merck & Co Inc., Celgene Corporation, CombiMatrix Corporation, Abbott Laboratories and others. The role of these market players in the global nanomedicine market is analyzed by profiling them on the basis of attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments.

Moreover, the report highlighted revenue, sales, manufacturing cost, and product and the States that are most competitive in the lucrative market share idea. There is a discussion on the background and financial trouble in the global Nanomedicine economic market. This included the CAGR value during the outlook period leading to 2025.

Inimitable Expertise: Analysts will provide deep insights into the reports.

Analyst Support: Get your query resolved from our team before and after purchasing the report.

Customers Satisfaction: Our team will assist with all your research needs and customize the report.

Assured Quality: We focus on the quality and accuracy of the report.

Conclusively, this report will provide you a clear view of each and every fact of the market without a need to refer to any other research report or a data source. Our report will provide you with all the facts about the past, present, and future of the concerned Market.

Read more:
Addressing the potential impact of coronavirus disease (COVID-19) on Growth of Innovations in Nanomedicine Market by Major Players, Size, Industry...

Nanomedicine Marketwas valued US$ XX Bn in 2018 and is expected to reach US$ XX Bn by 2026, at CAGR of XX% during forecast period of 2019 to 2026.

The report study has analyzed revenue impact of covid-19 pandemic on the sales revenue of market leaders, market followers and disrupters in the report and same is reflected in our analysis.

Nanomedicine Market Drivers and Restrains:Nanomedicine is an application of nanotechnology, which are used in diagnosis, treatment, monitoring, and control of biological systems. Nanomedicine usages nanoscale manipulation of materials to improve medicine delivery. Therefore, nanomedicine has facilitated the treatment against various diseases. The nanomedicine market includes products that are nanoformulations of the existing drugs and new drugs or are nanobiomaterials. The research and development of new devices as well as the diagnostics will become, more effective, enabling faster response and the ability to treat new diseases are likely to boost the market growth.

REQUEST FOR FREE SAMPLE REPORT:https://www.maximizemarketresearch.com/request-sample/39223/

The nanomedicine markets are driven by factors such as developing new technologies for drug delivery, increase acceptance of nanomedicine across varied applications, rise in government support and funding, the growing need for therapies that have fewer side effects and cost-effective. However, long approval process and risks associated with nanomedicine (environmental impacts) are hampering the market growth at the global level. An increase in the out-licensing of nanodrugs and growth of healthcare facilities in emerging economies are likely to create lucrative opportunities in the nanomedicine market.

Nanomedicine Market Segmentation Analysis:Based on the application, the nanomedicine market has been segmented into cardiovascular, neurology, anti-infective, anti-inflammatory, and oncology. The oncology segment held the dominant market share in 2018 and is projected to maintain its leading position throughout the forecast period owing to the rising availability of patient information and technological advancements. However, the cardiovascular and neurology segment is projected to grow at the highest CAGR of XX% during the forecast period due to presence of opportunities such as demand for specific therapeutic nanovectors, nanostructured stents, and implants for tissue regeneration.

Nanomedicine Market Regional Analysis:Geographically, the Nanomedicine market has been segmented into North America, the Europe, Asia Pacific, Latin America, and Middle East & Africa. North America held the largest share of the Nanomedicine market in 2018 due to the rising presence of patented nanomedicine products, the availability of advanced healthcare infrastructure and the rapid acceptance of nanomedicine. The market in Asia Pacific is expected to expand at a high CAGR of XX% during the forecast period thanks to rise in number of research grants and increase in demand for prophylaxis of life-threatening diseases. Moreover, the rising investments in research and development activities for the introduction of advanced therapies and drugs are predicted to accelerate the growth of this region in the near future.

DO INQUIRY BEFORE PURCHASING REPORT HERE:https://www.maximizemarketresearch.com/inquiry-before-buying/39223/

Nanomedicine Market Competitive landscapeMajor Key players operating in this market are Abbott Laboratories, CombiMatrix Corporation, General Electric Company, Sigma-Tau Pharmaceuticals, Inc, and Johnson & Johnson. Manufacturers in the nanomedicine are focusing on competitive pricing as the strategy to capture significant market share. Moreover, strategic mergers and acquisitions and technological innovations are also the key focus areas of the manufacturers.

The objective of the report is to present a comprehensive analysis of Nanomedicine Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all aspects of the industry with a dedicated study of key players that includes market leaders, followers and new entrants by region. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors by region on the market are presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers. The report also helps in understanding Nanomedicine Market dynamics, structure by analyzing the market segments and project the Nanomedicine Market size. Clear representation of competitive analysis of key players By Type, Price, Financial position, Product portfolio, Growth strategies, and regional presence in the Nanomedicine Market make the report investors guide.Scope of the Nanomedicine Market:

Nanomedicine Market by Modality:

Diagnostics TreatmentsNanomedicine Market by Diseases:

Oncological Diseases Infectious Diseases Cardiovascular Diseases Orthopedic Disorders Neurological Diseases Urological Diseases Ophthalmological Diseases Immunological DiseasesNanomedicine Market by Application:

Neurology Cardiovascular Anti-Inflammatory Anti-Infectives OncologyNanomedicine Market by Region:

Asia Pacific North America Europe Latin America Middle East AfricaNanomedicine Market Major Players:

Abbott Laboratories CombiMatrix Corporation General Electric Company Sigma-Tau Pharmaceuticals, Inc Johnson & Johnson Mallinckrodt plc. Merck & Company, Inc. Nanosphere, Inc. Pfizer, Inc. Teva Pharmaceutical Industries Ltd. Celgene Corporation UCB (Union Chimique Belge) S.A. AMAG Pharmaceuticals Nanospectra Biosciences, Inc. Arrowhead Pharmaceuticals, Inc. Leadiant Biosciences, Inc. Epeius Biotechnologies Corporation Cytimmune Sciences, Inc.

MAJOR TOC OF THE REPORT

Chapter One: Nanomedicine Market Overview

Chapter Two: Manufacturers Profiles

Chapter Three: Global Nanomedicine Market Competition, by Players

Chapter Four: Global Nanomedicine Market Size by Regions

Chapter Five: North America Nanomedicine Revenue by Countries

Chapter Six: Europe Nanomedicine Revenue by Countries

Chapter Seven: Asia-Pacific Nanomedicine Revenue by Countries

Chapter Eight: South America Nanomedicine Revenue by Countries

Chapter Nine: Middle East and Africa Revenue Nanomedicine by Countries

Chapter Ten: Global Nanomedicine Market Segment by Type

Chapter Eleven: Global Nanomedicine Market Segment by Application

Chapter Twelve: Global Nanomedicine Market Size Forecast (2019-2026)

Browse Full Report with Facts and Figures of Nanomedicine Market Report at:https://www.maximizemarketresearch.com/market-report/nanomedicine-market/39223/

About Us:

Maximize Market Research provides B2B and B2C market research on 20,000 high growth emerging technologies & opportunities in Chemical, Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

Contact info:

Name: Lumawant Godage

Organization: MAXIMIZE MARKET RESEARCH PVT. LTD.

Email: sales@maximizemarketresearch.com

Contact: +919607065656/ +919607195908

Website: http://www.maximizemarketresearch.com

Original post:
Nanomedicine Market : Industry Analysis and forecast 2026 - MR Invasion

The experiments took place in two plexiglass boxes connected by a tube. In one chamber, the team created a cloud of particles and blew them toward the tube, which was covered by different combinations of cloth. Mike Schmoldt and Greg Moss, environmental safety experts at Argonne who specialize in respirator testing and the effects of aerosol particles, used laboratory-grade scientific instruments to measured the number and size of particles in the chambers before and after passing through the fabric.

According to their results, one layer of a tightly woven cotton sheet, combined with two layers of polyester-based chiffona sheer fabric often used in evening gownsfiltered out the most aerosol particles (80% to 99%, depending on particle size). Substituting the chiffon with natural silk or a polyester-cotton flannel, or simply using a cotton quilt with cotton-polyester batting, produced similar results.

Though the study does not attempt to replicate real-world conditions, the findings are a useful guide. The researchers pointed out that tightly woven fabrics, such as cotton, can act as a mechanical barrier to particles; whereas fabrics that hold a static charge, like certain types of chiffon and natural silk, can serve as an electrostatic barrier. The electrostatic effect serves to suck in and hold the tiniest particles, which might otherwise slip through holes in the cotton. This is key to how N95 masks are constructed.

However, Guha added, even a small gap reduced the filtering efficiency of all masks by half or more, emphasizing the importance of a properly fitted mask.

Fabrics that did not do well included standard polyester and spandex with more open weave. In general, Guha said, fabric with tighter weaveswith fewer gaps between the strands of yarnworked better.

This is some of the first methodical data Ive seen on homemade masks. Its very helpful to have some idea of how the different types of fabric perform, said Emily Landon, executive medical director of infection prevention and control at the University of Chicago Medicine. I was also pleasantly surprised by how effective some of the homemade masks can be in the right conditions.

Landon noted that the advice to wear homemade masks while out in public is intended primarily to protect others from your own respiratory droplets, and that universal adoption of this recommendation will go a long way to make everyone safer.

In that case, any mask is better than none.

The first author on the study was Abhiteja Konda with Argonne National Laboratory. The other authors were Argonnes Abhinav Prakash as well as Pritzker School of Molecular Engineering graduate student Gregory Grant. The team used the U.S. Department of Energys Center for Nanoscale Materials user facility at Argonne National Laboratory.

Citation: Aerosol Filtration Efficiency of Common Fabrics Used in Respiratory Cloth Masks. Konda et al, ACS Nano, April 24, 2020. https://doi.org/10.1021/acsnano.0c03252

Funding: partly supported by the U.S. Department of Defense Vannevar Bush Fellowship

Read more:
Homemade masks made of silk and cotton may boost protection - UChicago News

The world is not only fighting a health pandemic but also an economic one, as the Novel Coronavirus (COVID 19) casts its long shadow over economies around the globe. The complete lockdown situation in several countries, has directly or indirectly impacted many industries causing a shift in activities like supply chain operations, vendor operations, product commercialization, etc. In the latest report on Nanomedicine Market, published by Market Research Intellect, numerous aspects of the current market scenario have been taken into consideration and a concise analysis has been put together to bring you with a study that has Pre- and Post-COVID market analysis. Our analysts are watching closely, the growth and decline in each sector due to COVID 19, to offer you with quality services that you need for your businesses. The report encompasses comprehensive information pertaining to the driving factors, detailed competitive analysis about the key market entities and relevant insights regarding the lucrative opportunities that lie in front of the industry players to mitigate risks in such circumstances.

It offers detailed research and analysis of key aspects of the global Nanomedicine market. The market analysts authoring this report has provided detailed information on growth drivers, restraints, challenges, trends, and opportunities to offer a complete analysis of the global Nanomedicine market. Market participants can use the market analysis to plan effective growth strategies and prepare for future challenges in advance. Each trend in the global Nanomedicine market is carefully analyzed and investigated by market analysts.

For Better Understanding, Download Sample PDF Copy of Nanomedicine Market Research Report @ https://www.marketresearchintellect.com/download-sample/?rid=201321&utm_source=LHN&utm_medium=888

**Our SAMPLE COPY of the report gives a brief introduction of the Nanomedicine market, Detailed TOC, key players of the market, list of tables and figures and comprising key countries regions.**

The Major Players in Global Nanomedicine Market:

Global Nanomedicine Market Segmentation

This market was divided into types, applications and regions. The growth of each segment provides an accurate calculation and forecast of sales by type and application in terms of volume and value for the period between 2020 and 2026. This analysis can help you develop your business by targeting niche markets. Market share data are available at global and regional levels. The regions covered by the report are North America, Europe, the Asia-Pacific region, the Middle East, and Africa and Latin America. Research analysts understand the competitive forces and provide competitive analysis for each competitor separately.

To get Incredible Discounts on this Premium Report, Click Here @ https://www.marketresearchintellect.com/ask-for-discount/?rid=201321&utm_source=LHN&utm_medium=888

Nanomedicine Market Region Coverage (Regional Production, Demand & Forecast by Countries etc.):

North America (U.S., Canada, Mexico)

Europe (Germany, U.K., France, Italy, Russia, Spain etc.)

Asia-Pacific (China, India, Japan, Southeast Asia etc.)

South America (Brazil, Argentina etc.)

Middle East & Africa (Saudi Arabia, South Africa etc.)

Some Notable Report Offerings:

-> We will give you an assessment of the extent to which the market acquire commercial characteristics along with examples or instances of information that helps your assessment.

-> We will also support to identify standard/customary terms and conditions such as discounts, warranties, inspection, buyer financing, and acceptance for the Nanomedicine industry.

-> We will further help you in finding any price ranges, pricing issues, and determination of price fluctuation of products in Nanomedicine industry.

-> Furthermore, we will help you to identify any crucial trends to predict Nanomedicine market growth rate up to 2026.

-> Lastly, the analyzed report will predict the general tendency for supply and demand in the Nanomedicine market.

Have Any Query? Ask Our Expert@ https://www.marketresearchintellect.com/need-customization/?rid=201321&utm_source=LHN&utm_medium=888

Table of Contents:

Study Coverage: It includes study objectives, years considered for the research study, growth rate and Nanomedicine market size of type and application segments, key manufacturers covered, product scope, and highlights of segmental analysis.

Executive Summary: In this section, the report focuses on analysis of macroscopic indicators, market issues, drivers, and trends, competitive landscape, CAGR of the global Nanomedicine market, and global production. Under the global production chapter, the authors of the report have included market pricing and trends, global capacity, global production, and global revenue forecasts.

Nanomedicine Market Size by Manufacturer: Here, the report concentrates on revenue and production shares of manufacturers for all the years of the forecast period. It also focuses on price by manufacturer and expansion plans and mergers and acquisitions of companies.

Production by Region: It shows how the revenue and production in the global market are distributed among different regions. Each regional market is extensively studied here on the basis of import and export, key players, revenue, and production.

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage and more. These reports deliver an in-depth study of the market with industry analysis, market value for regions and countries and trends that are pertinent to the industry.

Contact Us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Tags: Nanomedicine Market Size, Nanomedicine Market Growth, Nanomedicine Market Forecast, Nanomedicine Market Analysis

Our Trending Reports

Commercial Greenhouse Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Deep Learning Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Digital Out Of Home Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Follow this link:
Nanomedicine Market Overview, Top Companies, Region, Application and Global Forecast by 2026 - Latest Herald

REDWOOD CITY, Calif., April 21, 2020 (GLOBE NEWSWIRE) -- Graybug Vision, Inc., a clinical stage biopharmaceutical company focused on developing transformative medicines to treat vision-threatening diseases of the retina and optic nerve, announces that a recent publication of the article Sustained treatment of retinal vascular diseases with self-aggregating sunitinib microparticles in Nature Communications was recognized as an Editors Highlight by the journal.

The article details the findings of a collaborative preclinical research project involving scientists at Graybug Vision and the Johns Hopkins University School of Medicine. The researchers developed a novel non-inflammatory polymer microparticle formulation containing sunitinib, an approved tyrosine kinase inhibitor drug that blocks vascular endothelial growth factor (VEGF) receptors. The microparticle formulation was specifically designed to self-aggregate into a depot in the eye.

The study demonstrated that a single intravitreal (IVT) injection of sunitinib microparticles potently suppresses choroidal neovascularization in a mouse model for six months, far longer than the effect of an IVT injection of aflibercept in the same model. The sunitinib microparticles were also shown to block VEGF-induced leukostasis and retinal nonperfusion, which are associated with the progression of diabetic retinopathy.

The invention of new compositions and methods to produce non-inflammatory polymer microparticles for the eye was a key achievement in prior research led by Justin Hanes, Ph.D., Lewis J. Ort Professor of Ophthalmology and Director of the Center of Nanomedicine at the Johns Hopkins University School of Medicine, and Peter J. McDonnell, Director of the Wilmer Eye Institute at Johns Hopkins. Graybug Vision was founded on the basis of technologies initially developed by Justin Hanes in collaboration with co-author Peter A. Campochiaro, M.D., Professor of Ophthalmology and Director of the Retinal Cell and Molecular Laboratory at Johns Hopkins School of Medicine.

VEGF signaling plays a critical role in retinal diseases like wet age-related macular degeneration, and our experiments with the sunitinib sustained-release formulation showed efficacy and durability, said Ming Yang, Vice President of Research and Development at Graybug Vision. Based on the results reported in this publication, Graybug advanced GB-102 into clinical development to evaluate its potential to improve the lives of patients with ocular diseases, concluded Ming Yang.

GB-102, Graybugs microparticle depot formulation of the anti-VEGF sunitinib malate, is currently in Phase 2 clinical development in patients with wet age-related macular degeneration (wet AMD). It seeks to reduce the need for frequent IVT injections by expanding treatment duration to six months while reducing the burden of current treatments.

About Wet AMDWet AMD is one of the most common retinal diseases, leading to vision decline caused by excess VEGF. VEGF is a protein produced by cells that stimulates the formation of abnormal new blood vessels behind the retina, called choroidal neovascularization. The leakage of fluid and protein from the vessels causes retinal degeneration and leads to severe and rapid loss of vision. Early intervention is essential to treat wet AMD. According to the American Academy of Ophthalmology, the prevalence of wet AMD in the United States is estimated at 1.75 million people. We estimate that approximately 20 million adults are affected by wet AMD worldwide.

About Graybug VisionGraybug Vision is a clinical stage biopharmaceutical company focused on developing transformative medicines to treat diseases of the retina and optic nerve. The companys proprietary ocular delivery technologies are designed to maintain effective drug levels in ocular tissue for up to six months and potentially longer, improving patient compliance, reducing healthcare burdens and ultimately delivering better clinical outcomes. Graybugs lead product candidate, GB-102, a microparticle depot formulation of sunitinib malate, inhibits multiple neovascular pathways for the intravitreal treatment of retinal diseases, including wet age-related macular degeneration, with a six-month dosing regimen. This approach is differentiated from the current standard of care, which requires more frequent dosing and primarily targets one neovascular pathway. Graybug is also using its proprietary technologies to develop GB-401, an injectable depot formulation of a beta-adrenergic prodrug, for primary open angle glaucoma, with a dosing regimen of once every six months or longer, and GB-103, a longer-acting version of GB-102, designed to maintain therapeutic drug levels in the retinal tissue for 12 months with a single injection. Founded in 2011 on the basis of technology licensed from the Johns Hopkins University School of Medicine, Graybug is headquartered in Redwood City, California. For more information, please visitwww.graybug.com.

Story continues

Read this article:
Nature Communications Highlights Research by Scientists at Graybug Vision and Johns Hopkins University on Sustained Treatment of Retinal Diseases -...

Taiwan develops AI infrared thermometer. (NHRI image) Taiwan develops AI infrared thermometer. (NHRI image)

TAIPEI (Taiwan News) Many Southeast Asian nations have expressed interest in acquiring a next-generation infrared thermometer developed by Taiwan that is being touted as smart and able to reduce erroneous readings.

Designed by the National Health Research Institutes (NHRI), a government-sponsored and mission-oriented medical research center, the thermometer incorporates artificial intelligence (AI) technologies.

The AI feature allows the device to detect people's faces before reading their temperatures, which reduces errors due to interference by radiation emitted from objects held by the individual being measured for example, a cup of hot coffee or cold drink. The feature is particularly commercially attractive at a time when countries around the world are deploying thermometers to screen suspected patients of the coronavirus.

Compared to other types of contactless thermometer, the system delivered satisfactory results in an experiment of 200 people in open spaces, said Liao Lun-de (), assistant investigator of NHRIs Institute of Biomedical Engineering and Nanomedicine. The masks, hats, and glasses the individuals wore were not found to have affected the temperature readings.

The device will sound an alarm and automatically take photos of individuals whose temperatures exceed a certain level. The alerts will be dispatched to disease control staff so they can respond in an efficient and timely fashion.

The mechanism, which integrates real-time thermal sensor software and AI neuroscience, among other technologies, is also cost-competitive, as some thermometers are priced at over NT$200,000 (US$6,653) a unit, said Liao.

Read the original here:
Taiwan's AI thermometer draws interest in SE Asia - Taiwan News

Share

Share

Email

After more than 20 years of research, we are now witnessing a breakthrough of small interfering RNA (siRNA)-based therapies. In 2018, the first-ever siRNA drug, Onpattro, reached the market, followed by the approval of Givlaari in 2019, and many other clinical trials are in progress.

Holding the potential to treat a wide range of diseases from cancer to immunological disorders, siRNA therapeutics have received plenty of attention. With the support of a suitable delivery system, they can be directed to downregulate a specific target gene. Both approved siRNA drugs Onpattro and Givlaari are only able to reach the liver, however. Other organs that can be treated by loco-regional administration, such as the lung, are, in principle, good targets for siRNA therapies as well.

In this view, siRNA-baseddrugs could not only act as an ally in the battle against the current COVID-19pandemic but also against other severe lung diseases such as asthma. Despitethe great advances in asthma treatment, this disease still represents an unmetmedical need in about 510% of patients.Moreover, most of the available drugs work symptomatically rather than causally.

In a recent article published in WIREs Nanomedicine and Nanobiotechnology, Domizia Baldassi and Tobias Keil, graduate students in Prof. Olivia Merkels research group at the University of Munich, discuss the groups advances towards developing a nanocarrier that can deliver siRNA into T cells in the lung.

The aim of T-cell delivery is downregulation of GATA-3, the transcription factor of T helper 2 (TH2) cells overexpressed in asthmatic patients, which is recognized as a key factor in the asthmatic inflammatory cascade. Based on their observation that transferrin receptor is overexpressed in activated T cells, the researchers sought to find a virus-like tool to target activated TH2 cells specifically and efficiently in a receptor-mediated manner.

They accomplishedthis goal by creating a conjugate formed by transferrin and low-molecular-weightpolyethylenimine (Tf-PEI). On the one hand, they used a well-known cationic polymerto electrostatically interact with the negatively charged siRNA and protect itfrom degradation during the journey through the airways. And on the other hand,transferrin served as a targeting moiety to mediate a specific, targeteddelivery of siRNA only to activated T cells.

Since theendosomal escape is considered the rate-limiting step in cytoplasmaticdelivery of nanoparticle-based therapies, improving this aspect of theformulation was the focus, and Tf-PEI was blended with a second conjugatecomposed of melittin and PEI (Mel-PEI). Melittin is a well-known membranolyticagent from bee venom that was chemically modified to react in a pH-dependentmanner.

The researchersexploited the intrinsic lytic characteristic of the peptide to improve therelease of siRNA into the cytosol, reaching knockdown levels as high as 70% exvivo. But further steps such as the validation of these results in vivo on anasthma mouse model are needed, as well as possible alternative polymericmaterials.

In the process of developing a new pharmaceutical product, it is crucial to keep the administration route in mind. Spray drying is the most straightforward technique to produce inhalable particles for pulmonary delivery, according to the researchers. In a proof-of-concept study, they obtained nano-in-microparticles by spray drying PEI-pDNA polyplexes together with a cryoprotectant agent. After seeing promising results, their studies to obtain a dry powder formulation of siRNA-based polyplexes are ongoing.

Ultimately, both research fields will be combined and hopefully result in a new therapy for the treatment of severe, uncontrolled asthma and many other lung diseases, concluded Baldassi, Keil, and Merkel.

Reference: Tobias W. M. Keil et al. T-cell targeted pulmonary siRNA delivery for the treatment of asthma. WIREs Nanomedicine and Nanobiotechnology (2020). DOI: 10.1002/10.1002/wnan.1634

Read this article:
A new, inhaled siRNA therapeutic option for asthma - Advanced Science News

Global Nano Therapy Market was valued US$ XX Mn in 2019 and is expected to reach US$ XX Mn by 2027, at a CAGR of 8.6% during a forecast period.

Global Nano Therapy Market

Market Dynamics

Nanotechnology is the manipulation of matter on an atomic, molecular, and supramolecular scale. Nanotherapy is a branch of Nano medicine that includes using nanoparticles to deliver a drug to a given target location in the body so as to treat the disease through a process called as targeting.

This report provides insights into the factors that are driving and restraining the global Nano Therapy market. Nanotherapy is also referred to as targeted therapy, which offers to transport the molecules to the affected cells to treat the disease without affecting other negative effects on the healthy cells. Nanoparticles allow for multiple functional groups to be added to the surface. Each of the functional groups contributes to the effectiveness of this method of therapy and deliver its components in a controlled way once it gets to the target cells/tissue. Nano therapy is considered as recent technology for some diseases, which are implemented with the help of submicron-sized molecular devices or nanoparticles. Nanoparticles can improve the drug accessibility in the body with strength, drag out the medication, and can upsurge the half-life of plasma and boost the drug specificity. These are the factors driving the growth of the Nano therapy market.

REQUEST FOR FREE SAMPLE REPORT: https://www.maximizemarketresearch.com/request-sample/54507

As compared to the conventional methods, this method has increased more popularity owing to its high accuracy when it comes to administering therapeutic formulations. The market is thriving, with around 250 Nano-medical products being verified or used for humans. Though, with Nano therapy, the carrier is protected from degradations, which allows it to reach given target cells in the body for a local reaction. Nano therapy is considerably used in the treatment of diseases like cancer, diabetes, and cardiovascular diseases. A recent study by the Journal of Diabetes and Metabolic diseases has stated that the incidence of MS ranged from 30.5 to 31.5% in China and 35.8 to 45.3% in India.

However, an absence of controlling standards in the examination of Nano therapy and high expenditure of treatment are several of the major factors that are restraining the growth of the Nano therapy market during the forecast period.

Global Nano Therapy Market Segment analysis

Based on Type, the Nanomaterial segment is anticipated to grow at a CAGR of 20.8% during the forecast period. The nanomaterial is the materials with at least one exterior dimension in the size range of nearly 1 to 100 nanometers. The nanomaterial is intended for developing novel characteristics and has the potential to improve quality of life. The nanomaterial is generally used in cosmetics, healthcare, electronics, and other areas currently. Unceasing development and innovation in the field are impelling the growth of the global nanomaterials market. The amazing chemical and physical properties of materials at the nanometer scale allow novel applications. For instance, energy conservation and structural strength improvement to antimicrobial properties and self-cleaning surfaces. Nanotechnology is being increasingly efficient by spending mainly on R&D activities which are resulting in the development of current technologies and innovations with reference to the new materials.

Global Nano Therapy Market Regional analysis

North America region dominated the Nano therapy market with US$ XX Mn in 2019. The availability of technology, increasing healthcare spending, and government funding for research and development are some of the factors boosting the growth of the Nano therapy market in the region. Europe is expected to follow the Americas and bring in the second leading market share for Nano therapy throughout the forecast period. Europe is mainly driven by awareness and improvement in the nanotechnology sector.

Recent Developments

In 08 May 2019- Cisplatin cis-(diammine) dichloridoplatinum (II) (CDDP) is the first platinum based complex approved by the food and drug administration (FDA) of the United States (US). Cisplatin is the first line chemotherapeutic agent used alone or combined with radiations or other anti-cancer agents for a broad range of cancers such as lung, head and neck.

In May 2019- A new study conducted by scientists from the Indian Institute of Technology, Bombay, have designed hybrid nanoparticles to treat cancer. These nanoparticles are made from gold and lipids. These nanoparticles respond to light and can be directed inside the body to release drugs to a targeted area, and are biocompatible, meaning theyre not toxic to a human body.

In September 2019, researchers at Finlands University of Helsinki, in partnership with the bo Akademi University and Chinas Huazhong University of Science and Technology developed an anti-cancer nanomedicine useful for targeted cancer chemotherapy.

The objective of the report is to present a comprehensive analysis of the Global Nano Therapy Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that includes market leaders, followers and new entrants. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors of the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers.The report also helps in understanding Global Nano Therapy Market dynamics, structure by analyzing the market segments and project the Global Nano Therapy Market size. Clear representation of competitive analysis of key players by Application, price, financial position, Product portfolio, growth strategies, and regional presence in the Global Nano Therapy Market make the report investors guide.Scope of the Global Nano Therapy Market

DO INQUIRY BEFORE PURCHASING REPORT HERE: https://www.maximizemarketresearch.com/inquiry-before-buying/54507

Global Nano Therapy Market, By Type

Nanomaterial and Biological Device Nano Electronic Biosensor Molecular Nanotechnology Implantable Cardioverter-DefibrillatorsGlobal Nano Therapy Market, By Application

Cardiovascular Disease Cancer Therapy Diabetes Treatment Rheumatoid ArthritisGlobal Nano Therapy Market, By Regions

North America Europe Asia-Pacific South America Middle East and Africa (MEA)Key Players operating the Global Nano Therapy Market

Selecta Biosciences Inc. Cristal Therapeutics Sirnaomics Inc. Nanobiotix Luna CytImmune Science Inc. NanoBio Corporation Nanospectra Biosciences Inc. Nanoprobes Inc. NanoBioMagnetics.n.nu Smith and Nephew NanoMedia Solutions Inc. Nanosphere Inc. DIM Parvus Therapeutics Tarveda Therapeutics

MAJOR TOC OF THE REPORT

Chapter One: Nano Therapy Market Overview

Chapter Two: Manufacturers Profiles

Chapter Three: Global Nano Therapy Market Competition, by Players

Chapter Four: Global Nano Therapy Market Size by Regions

Chapter Five: North America Nano Therapy Revenue by Countries

Chapter Six: Europe Nano Therapy Revenue by Countries

Chapter Seven: Asia-Pacific Nano Therapy Revenue by Countries

Chapter Eight: South America Nano Therapy Revenue by Countries

Chapter Nine: Middle East and Africa Revenue Nano Therapy by Countries

Chapter Ten: Global Nano Therapy Market Segment by Type

Chapter Eleven: Global Nano Therapy Market Segment by Application

Chapter Twelve: Global Nano Therapy Market Size Forecast (2019-2026)

Browse Full Report with Facts and Figures of Nano Therapy Market Report at: https://www.maximizemarketresearch.com/market-report/global-nano-therapy-market/54507/

About Us:

Maximize Market Research provides B2B and B2C market research on 20,000 high growth emerging technologies & opportunities in Chemical, Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

Contact info:

Name: Lumawant Godage

Organization: MAXIMIZE MARKET RESEARCH PVT. LTD.

Email: sales@maximizemarketresearch.com

Contact: +919607065656/ +919607195908

Website: http://www.maximizemarketresearch.com

Visit link:
Global Nano Therapy Market- Industry Analysis and Forecast (2020-2027) - Publicist360

Share

Share

Email

Althoughthe medical and pharmaceutical fields have come a long way in diagnosing diseasestates and producing highly potent drugs, the lack of effective delivery ofsuch therapeutics to the target organ with desired pharmacokinetics remains oneof the major challenges in this process.

The advent of nanotechnology, along with advances in protein engineering and materials science, have brought new hope to patients. The impact of nanotechnology on medicine nanomedicine is recognized by the development of novel nanoscale therapeutics and diagnostic and imaging modalities.

Ina recent review published in WIREs Nanomedicine and Nanobiotechnology, Professor Joerg Lahann and his team from the University of Michigan discuss state-of-the-art nanoparticle drug delivery platforms, their advantages and shortcomings, and future directions towards clinical translation.

The ability to impart multiple functions to a single delivery system, engineering both bulk and surface properties, provides a means to answer some of the greatest remaining challenges in the field of drug delivery, said Jason Gregory, a PhD student in the Lahann Lab.

In fact, approaches to address this conundruminclude the development of multifunctional particles, cell-mediated transportmechanisms, and the use of biologically derived materials. Multifunctionalparticles can possess two or more dissimilar properties through surface or bulkanisotropy.

For example, the electrohydrodynamic co-jetting process, which was pioneered in the Lahann lab, permits the creation of multicompartmental particles. Independently engineering individual compartments of the nanoparticle leads to an ability to incorporate materials with orthogonal properties that may offer a solution to simultaneously address multiple biological barriers.

Multicompartmental particles provide a set ofunique features for nanoparticle targeting and controlled release ofcombination drugs, said Dr. Joerg Lahann, the Wolfgang Pauli CollegiateProfessor of Chemical Engineering and Director of the Biointerfaces Instituteat the University of Michigan.

While traditional nanoparticles fail to efficiently deliver the drug to target sites, our bodys circulatory cells as natural carriers of many substances have evolved properties to optimally perform delivery functions. Imparting these properties into the design of the drug delivery platforms by combining nanoparticles with circulatory cells enhances the overall outcome of the system, added Nahal Habibi, a PhD student in the Lahann Lab working on cell-mediated drug delivery strategies.

Leukocytes are particularly good candidates because they can naturally migrate to disease-relevant regions that are often inaccessible by traditional nanoparticles, and have been used to carry therapeutic nanoparticles to cross the bloodbrain barrier in a Parkinsons disease model.

Synthetic protein nanoparticles are another emerging trend in nanomedicine.

Advances in designing novel multicompartmental polymer/protein nanoparticles utilizing the intersection of polymer chemistry and protein biochemistry offers promise in engineering the next generation of nanoparticle formulations, said Daniel Quevedo, another PhD candidate in Prof. Lahanns group.

Reference: Nahal Habibi et al. Emerging methods in therapeutics using multifunctional nanoparticles. WIREs Nanomedicine and Nanobiotechnology (2020). DOI: 10.1002/wnan.1625

Read the original here:
Multifunctional nanomedicine: Developing smarter therapeutics - Advanced Science News

Mauro Ferrari resigned unexpectedly as president of the European Research Council, triggering a noisy public spat over why and how he left.

Ferrari, an Italian-American expert in nano-medicine, fired off an angry resignation memo provided first to the Financial Times castigating the European Commission for a largely uncoordinated cluster of initiatives. He said he pushed to have the ERC, which focuses on frontier research, launch a special funding round for COVID-19 research. As a result, he said, I have lost faith in the system itself and submitted his resignation on 7 April.

But that version of events was quickly disputed in Brussels. Christian Ehler, a German member of the European Parliament who leads research legislation, issued a late-night statement calling Ferraris actions a window-dressing public relations stand on the coronavirus crisis and it was a contradiction to the legal basis of the ERC.

Other sources said the agencys governing body, the 21-member Scientific Council, had decided days earlier to ask for Ferraris resignation. Among the issues was a belief that he was spending too much time on non-ERC, private activities.

The Commission issued a statement confirming Ferraris immediate resignation and noting that his contract as ERC president only gave him the legal powers of a special advisor to the Commission. Legally, it said, the Scientific Council defines the scientific funding strategy and methodologies of the ERC. It went on to thank him for the strong personal investment he made in the months leading up to his appointment 1 January.

When he took office on 1 January, Ferrari was allowed to continue some outside activities back in the US, where he had built his career in engineering, nanotechnology and medicine. Among these was a paid board position at a US biotech company, Arrowhead Pharmaceuticals. He also continued as an affiliate professor in pharmaceutical science at the University of Washington. But the arrangement was unusual for an agency like the ERC, and had already prompted some outside criticism. As European nations began entering COVID-19 lockdown last month, he was in the US, where his grown children work.

A Commission spokesman late on 7 April confirmed Ferraris resignation, but declined to elaborate. Ferrari couldnt be reached immediately for direct comment, but the Financial Times published his statement excoriating the ERC and the Commission.

In the statement, he said that he proposed that the ERC set up a special COVID-19 programme, because at a time like this, the very best scientists in the world should be provided with resources and opportunities to fight the pandemic. He said it was rejected unanimously by the Scientific Council without even considering what shape or form it may take. He added that he was later invited by Commission President Ursula von der Leyen for my input on COVID-19, which created an internal political thunderstorm inside the Commission bureaucracy.

The ERC, by law, funds research proposed directly by scientists based on their own judgment of whats important; they get the money - 2.2 billion in all for 2020 if peer review panels organised by the agency agrees with them. Ferraris statement says he knew his idea for top-down COVID-19 grants ran counter to the agencys normal bottom-up practice, but it was justified by the emergency.

Agency officials declined to comment publicly, but the MEP, Ehler, issued a public defence of the ERC, pushing back at Ferrari.

Besides calling Ferraris COVID-19 plan window-dressing, Ehler said Ferrari was never really acquainting with the independent nature of the ERC. He continued: We are sorry that things have turned out this way for a brilliant researcher and entrepreneur like Mr. Ferrari. However, this should not serve as argument to accuse the ERC or the EU of not doing enough.

The ERC focuses on fundamental rather than applied research and numbers among its existing grantees virologists, epidemiologists and others who have been doing basic research for the agency, and have now joined applied COVID-research teams in the Commissions other programmes.

They include 48.5 million for emergency Horizon 2020 collaborative projects for vaccines, cures and tools; 45 million to its Innovative Medicines Initiative; 80 million in financial support for German vaccine maker Curevac; and up to 164 million in grants to small business with COVID-19 solutions to develop.

On taking office in January, Ferrari quickly unveiled ambitious plans for the ERC. In an interview with Science|Business in February, he spoke enthusiastically of the need for what he called super-disciplinary research, in which scientists break out of their normal disciplines and think across domains. He was also a strong advocate of researchers helping to get their discoveries commercialised and into widespread use something he did repeatedly in his own career.

Ferrari, now 60 years old, is credited as one of the founders of nanomedicine. In 2016, his research team made headlines with a new cancer treatment that uses nanoparticles loaded with a chemotherapeutic to target metastatic cells directly, thereby minimising collateral damage to healthy tissue and allowing more sustained and aggressive treatment. Ferrari has around 480 publications to his name, with over 20,000 citations. He also holds dozens of patents for inventions including different varieties of nanoparticles for drug delivery.

Originally from northern Italy, he studied mathematics at the University of Padua before moving to University of California, Berkeley, where he studied for a masters and a PhD in mechanical engineering. He went on to become an associate professor at Berkeley and moved into medicine when he became a professor of bioengineering and mechanical engineering at Ohio State University.

Ferrari later moved to the MD Anderson Center and the University of Texas Health Science Center in Houston. In 2010 he became president and CEO of the Houston Methodist Research Institute.

Read more:
Sudden resignation of ERC president stirs heated dispute over motives - Science Business

Toshio Ando is internationally recognized for the development and invention of the in-liquid high-speed atomic force microscope (HS-AFM) for visualizing the dynamics of protein molecules in liquid environments [1-6]. The publication of his seminal paper on HS-AFM in 2008 led Ando and his colleagues to develop derivatives of this technology including non-invasive high-speed scanning ion-conductance microscopy (HS-SICM). "It is a great honor for me to receive this HFSP grant in the worldwide competition," says Professor Ando.

Comments from the HFSP highlighted the strengths of the team and multidisciplinary nature of the proposal, stating: "This is a very strong team of investigators. Each is highly accomplished in their field and brings unique expertise."

Roles of the members of the team:

The Human Frontier Science Program (HFSP) promotes international collaborative basic research on "the elucidation of the sophisticated and complex mechanisms of living organisms". The programs are implemented by the International Human Frontier Science Program Organization (HFSPO) that is based in Strasburg and receives financial support from the governments or research councils of the European Union, Australia, Canada, France, Germany, India, Italy, Japan, Republic of Korea, New Zealand, Norway, Singapore, Switzerland, United Kingdom, and USA.

Selection of references on research published by Professor Ando on high speed AFM

Prof. Toshio Ando

Prof. Toshio Ando

Further general information

About the Human Frontier Science Program2020 awards for Research Grants https://www.hfsp.org/awardees/newly-awarded

About WPI nanoLSI Kanazawa University

Hiroe YonedaVice Director of Public AffairsWPI Nano Life Science Institute (WPI-NanoLSI)Kanazawa UniversityKakuma-machi, Kanazawa 920-1192, JapanEmail: nanolsi-office@adm.kanazawa-u.ac.jpTel: +81(76)234-4550

About Nano Life Science Institute (WPI-NanoLSI)

Home

Nano Life Science Institute (NanoLSI), Kanazawa University is a research center established in 2017 as part of the World Premier International Research Center Initiative of the Ministry of Education, Culture, Sports, Science and Technology. The objective of this initiative is to form world-tier research centers. NanoLSI combines the foremost knowledge of bio-scanning probe microscopy to establish 'nano-endoscopic techniques' to directly image, analyze, and manipulate biomolecules for insights into mechanisms governing life phenomena such as diseases.

About Kanazawa University

http://www.kanazawa-u.ac.jp/e/

As the leading comprehensive university on the Sea of Japan coast, Kanazawa University has contributed greatly to higher education and academic research in Japan since it was founded in 1949. The University has three colleges and 17 schools offering courses in subjects that include medicine, computer engineering, and humanities.

The University is located on the coast of the Sea of Japan in Kanazawa a city rich in history and culture. The city of Kanazawa has a highly respected intellectual profile since the time of the fiefdom (1598-1867). Kanazawa University is divided into two main campuses: Kakuma and Takaramachi for its approximately 10,200 students including 600 from overseas.

Photo: https://mma.prnewswire.com/media/1142295/Kanazawa_University.jpg

SOURCE Kanazawa University

Originally posted here:
Toshio Ando of the WPI Nano Life Science Institute, Kanazawa University and Colleagues From Greece, Germany, and USA Have Been Awarded The Prestigious...

VANCOUVER, March 25, 2020 /PRNewswire/ --Precision Nanosystems, Inc. (PNI), a global leader in enabling transformative nanomedicinesannounced today that the companyentered into a license agreement with FUJIFILM Corporationto adopt PNI's NanoAssemblr technology and complete suite of instruments for Fujifilm'sstate-of-the-art manufacturing facility, compatible with GMP regulations of US, Europe and Japan.

As part of this agreement, Fujifilm has the rights to offer contract manufacturing services using PNI's proprietary technology andalso use PNI technology to develop and commercialize its internal therapeutic drug products. PNI and Fujifilm will work together to combine and democratize the scalable manufacturing of gene therapy and small-molecule based nanomedicines using Fujifilm's and PNI's proprietary technologies.

PNI's NanoAssemblr technology is powered by the disruptive NxGen microfluidics mixing technology designed exclusively for scalable nanomedicine development while maintaining precise control and reproducibility. The NanoAssemblr platform is comprised of the Spark, Ignite, Blaze and GMP Systems that together offer a flexible solution for accelerated, cost-effective development and scalable manufacture of high-quality gene therapy, small molecule and protein-based nanomedicine products.

James Taylor, Co-Founder and CEO of PNI said, "We are thrilled to work with Fujifilm to enable our technology in support of clinical clients as they progress their therapeutic programs from the laboratory to the clinic and commercial. Fujifilm's R&D teams will combinethe PNI platform andtheir proprietary Drug Delivery Systems technologies and we look forward to the seamless scaling up and manufacturing of innovative medicines to impact human well-being."

Nanomedicinesis one of the focus areas of Fujifilm, tapping into itsadvanced technologies such as nano-technology, process engineering technology and analysis technology. "We are excited to work with PNI to bring on board the NanoAssemblr suite of products and cutting-edge nanomedicines manufacturing technology," said Junji Okada, Senior Vice President, General Manager of Pharmaceutical products division, FUJIFILM Corporation. "Tapping into Fujifilm's state of the art technology, expertise and thefacility for the provision of pre-clinical and GMP manufacturing services, we are committed to creating innovative and high-value pharmaceutical productsnot only through internal development but also by providing high quality liposomal formulations to our partner companies."

About Precision NanoSystems Inc.

Precision NanoSystems Inc. (PNI) proprietary NanoAssemblr Platform enables the rapid, reproducible, and scalable manufacture of next generation nanoparticle formulations for the targeted delivery of therapeutic and diagnostic agents to cells and tissues in the body. PNI provides instruments, reagents and services to life sciences researchers, including pharmaceutical companies, and builds strategic collaborations to revolutionize healthcare through nanotechnology. For more information, visit http://www.precisionnanosystems.com.

About Fujifilm CorporationFUJIFILM Corporation, Tokyo, Japan is one of the major operating companies of FUJIFILM Holdings Corporation. The company brings cutting edge solutions to a broad range of global industries by leveraging its depth of knowledge and fundamental technologies developed in its relentless pursuit of innovation. Its proprietary core technologies contribute to the various fields including healthcare, graphic systems, highly functional materials, optical devices, digital imaging and document products. These products and services are based on its extensive portfolio of chemical, mechanical, optical, electronic and imaging technologies. For the year ended March 31, 2019, the company had global revenues of $22 billion, at an exchange rate of 111 yen to the dollar. Fujifilm is committed to responsible environmental stewardship and good corporate citizenship. For more information, please visit: http://www.fujifilmholdings.com.

Jane Alleva, Global Marketing Manager, Precision NanoSystems, Phone: 1 888 618 0031, ext 140, mobile 1 778 877 5473

SOURCE Precision Nanosystems

Read more:
Precision NanoSystems Announces Partnership with Fujifilm for the Development and GMP Manufacturing of Nanoparticle Based Therapeutics - Yahoo Finance

KANAZAWA, Japan, March 25, 2020 /PRNewswire/ -- In a recent study published in Autophagy, researchers at Kanazawa University show how abnormalities in a gene called TPR can lead to pediatric brain cancer.

Ependymoma is a rare form of brain cancer that implicates children and is often tricky to diagnose. Since effective treatment options can be initiated only after a well-formed diagnosis, there is a dire need among the medical community to identify markers for ependymoma, which in turn, will help oncologists tailor therapy better. Richard Wong's and Mitsutoshi Nakada's team at Kanazawa University has now shown how one gene closely linked to ependymoma can help with not just diagnosis, but also treatment options for the condition.

A gene known as TPR shows an elevated presence in 38% of ependymoma cases. Thus, the team first sought out to investigate how an increase in the TPR gene correlated to the development of cancer cells. Each gene present in a cell contains a code for the creation of a specific protein. The TPR gene contains the code for an eponymous protein. Therefore, cancer samples from patients were assessed for the levels of TPR protein. As expected, levels of TPR were abnormally high in these tumor tissues.

The researchers then moved on to investigate whether these abnormal TPR levels could lead to cancer progression. For this purpose, mice were implanted with human ependymoma cancer tissue into their brains. The TPR gene was then deleted in these tissues so that the mice were unable to create the TPR protein. When the tumor tissues were subsequently analyzed, a reduction of cancer growth was seen. The TPR gene was thus vital for the growth of ependymoma tumors.

Deletion of the TPR protein is known to induce a process called autophagy within cells. Autophagy is initiated when a cell is under undue stress and results in the death of damaged cells. The patient tumor samples, with their high levels of TPR protein, showed little or no presence of autophagy. However, autophagy was remarkably high in the mice with TPR depletion. Ependymoma cells were thus spared of autophagic death due to the increased presence of TPR. These damaged cells continued to grow by circumventing the biological systems set up to keep them in check. The high TPR levels were also accompanied by an increase in HSF-1 and MTOR, molecules which are responsible for cell growth and survival.

Finally, the possibility of lowering TPR levels therapeutically to control the cancer was assessed. The mice were given a drug called rapamycin, which inhibits MTOR. The treatment not only led to decreased TPR levels, but also shrank the tumor tissues within their brains.

"Thus, TPR can serve as a potential biomarker, and MTOR inhibition could be an effective therapeutic approach for ependymoma patients," conclude the researchers. While looking out for increased levels of TPR in patients can help oncologists achieve a more comprehensive diagnosis, reducing TPR levels with the help of drugs can help keep the tumors in check.

Background:

Autophagy: Autophagy, which literally translates to "self-eating" is the self-preservation mechanism of the body to get rid of damaged cells. Autophagy is initiated when an abnormal amount of proteins or toxins build up within a cell, which the cell cannot clear out. Conditions like Alzheimer's disease and Parkinson's disease arise when autophagic mechanisms within the cells start malfunctioning. Impaired autophagy is also known to be implicated in driving various forms of cancer.

Reference

Firli Rahmah Primula Dewi, Shabierjiang Jiapaer, Akiko Kobayashi, Masaharu Hazawa, Dini Kurnia Ikliptikawati, Hartono, Hemragul Sabit, Mitsutoshi Nakada, and Richard W. Wong. "Nucleoporin TPR (translocated promoter region, nuclear basket protein) upregulation alters MTOR-HSF1 trails and suppresses autophagy induction in ependymoma", Autophagy. Published online 24March2020.

DOI 10.1080/15548627.2020.1741318.

About Nano Life Science Institute (WPI-NanoLSI)

Home

Nano Life Science Institute (NanoLSI), Kanazawa University is a research center established in 2017 as part of the World Premier International Research Center Initiative of the Ministry of Education, Culture, Sports, Science and Technology. The objective of this initiative is to form world-tier research centers. NanoLSI combines the foremost knowledge of bio-scanning probe microscopy to establish 'nano-endoscopic techniques' to directly image, analyze, and manipulate biomolecules for insights into mechanisms governing life phenomena such as diseases.

About Kanazawa University

http://www.kanazawa-u.ac.jp/e/

As the leading comprehensive university on the Sea of Japan coast, Kanazawa University has contributed greatly to higher education and academic research in Japan since it was founded in 1949. The University has three colleges and 17 schools offering courses in subjects that include medicine, computer engineering, and humanities.

The University is located on the coast of the Sea of Japan in Kanazawa a city rich in history and culture. The city of Kanazawa has a highly respected intellectual profile since the time of the fiefdom (1598-1867). Kanazawa University is divided into two main campuses: Kakuma and Takaramachi for its approximately 10,200 students including 600 from overseas.

Further information

Hiroe Yoneda Vice Director of Public AffairsWPI Nano Life Science Institute (WPI-NanoLSI)Kanazawa UniversityKakuma-machi, Kanazawa 920-1192, JapanEmail: nanolsi-office@adm.kanazawa-u.ac.jp Tel: +81-(76)-234-4550

SOURCE Kanazawa University

Read more here:
Kanazawa University Research: Insights into the Diagnosis and Treatment of Brain Cancer in Children - PR Newswire UK

Toronto, ON, March 18, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Ryerson researchers have a long history of successful collaborative R&D endeavors with Toronto Poly Clinic Inc. (a subsidiary of Tree of Knowledge International Corp. (TOKI)CSE: TOKI OTC: TOKIF) and more recently with TOKI. The novel nano-technology collaborative research project is investigating new ways of delivering cannabinoid molecules to target regions in the body for cancer therapy and pain management. Ryerson researchers received the Health Canada license under the Cannabis Act and Regulations to start the project on March 6, 2020. TOKI is the sponsor and clinical collaborator for the project.

"This Health Canada approval of a research license opens the way for new investigations on developing nano-medicine and delivery methods with cannabinoids. Targeted treatments are essential for many cancer therapies and pain conditions and our project with Ryerson researchers can now work with medical cannabis for our treatment goals. This has been a great milestone for our research," says Dr. Kevin Rod, the Chief Medical Advisor to TOKI.

The Ryerson research team is extremely pleased with this Health Canada license approval to start working on this novel and exciting collaborative R&D initiative. They anticipate building upon the jointly-developed nano-medicine and ultrasound technology platforms to further advance the novel field of targeted cannabinoid drug delivery for cancer treatment and pain management.

With its head office in Toronto, and operations in North York, Ontario, TOKI currently has three primary business segments: (1) Multidisciplinary specialty pain clinics with a focus on the treatment of chronic pain, (2) Development of formulated products for therapeutic purposes and natural health product alternatives at a GMP manufacturing facilityand (3) Distribution and sale of hemp-based cannabidiol (CBD) products in the United States, Europe, Brazil and Australia. Through its Toronto Poly Clinic, the Company has gleaned extensive expertise from being involved in one of the largest observational studies on medical cannabis and from its ongoing direct patient experience. The Company hasalsodeveloped and implemented MCORP (Medical Cannabis Opioid Reduction Program) with great success. Currently, the Companyis expanding its product line to include Health Canada approved Natural products for support of the immune system and general health and wellness during these challenging times of the Corona virus.

Contact:

Tree of Knowledge International Corp.

Michael Caridi

Chairman/CEO

michael@tokicorp.com

917.295.1374

About Tree of Knowledge

With its head office in Toronto, and operations in North York, Ontario and Spokane, Washington, TOKI currently has three primary business segments: (1) Multidisciplinary specialty pain clinics with a focus on the treatment of chronic pain, including controlled applications of medical cannabis in Canada, (2) Development of formulated products for therapeutic purposes and natural health product alternatives at a GMP manufacturing facilityand (3) Distribution and sale of hemp-based cannabidiol ("CBD") products in the United States, Canada, Europe, Brazil and Australia. Through its Toronto Poly Clinic, the Company has gleaned extensive expertise from being involved in one of the largest observational clinical trials on medical cannabis and from its ongoing direct patient experience. The Company has developed and implemented MCERP (Medical Cannabis Education, Research and Best Practice Platform) and MCORP (Medical Cannabis Opioid Reduction Program) with great success. Currently, the Company has research agreements with multiple universities for medical cannabis research and new medical grade products development. TOKI's CBD product line contains EVR Premium Hemp Oil, which is an organically grown and handled, gluten-free, vegan, non-GMO, synergistic compound that is derived from U.S. Department of Agriculture (USDA) approved industrial hemp grown in the United States. TOKI currently offers several CBD products, which may be used in connection with the treatment of a number of ailments and for general wellness purposes.

Notice Regarding Forward Looking Statements

This news release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995 and forward-looking information within the meaning of applicable Canadian securities legislation. Often, but not always, forward-looking statements and information can be identified by the use of words such as plans, expects or does not expect, is expected, estimates, intends, anticipates or does not anticipate, or believes, or variations of such words and phrases or state that certain actions, events or results may, could, would, might or will be taken, occur or be achieved. Forward-looking statements or information involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Canopy Growth or its subsidiaries to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements or information contained in this news release. Examples of such statements include statements with respect to future product format offerings. Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information, including the Companys ability to satisfy provincial sales contracts or provinces purchasing all cannabis allocated to them, and such risks contained in the Companys annual information form dated June 25, 2019 and filed with Canadian securities regulators available on the Companys issuer profile on SEDARat http://www.sedar.com.Although the Company believes that the assumptions and factors used in preparing the forward-looking information or forward-looking statements in this news release are reasonable, undue reliance should not be placed on such information and no assurance can be given that such events will occur in the disclosed time frames or at all. The forward-looking information and forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking information or forward-looking information to reflect new information, subsequent events or otherwise unless required by applicable securities laws.

The rest is here:
Health Canada Grants Cannabis Research License to the Joint R&D Project of Tree of Knowledge International Corp (TOKI) and Ryerson University -...

Rational design of potent antioxidative agent with high biocompatibility is urgently needed to treat ischemic reperfusion-induced ROS-mediated cerebrovascular and neural injury during ischemia strokes. Here, we demonstrate an in situ synthetic strategy of bioactive zeolitic imidazolate framework-8capped ceria nanoparticles (CeO2@ZIF-8 NPs) to achieve enhanced catalytic and antioxidative activities and improved stroke therapeutic efficacy. This nanosystem exhibits prolonged blood circulation time, reduced clearance rate, improved BBB penetration ability, and enhanced brain accumulation, where it effectively inhibits the lipid peroxidation in brain tissues in middle cerebral artery occlusion mice and reduces the oxidative damage and apoptosis of neurons in brain tissue. CeO2@ZIF-8 also suppresses inflammation- and immune responseinduced injury by suppressing the activation of astrocytes and secretion of proinflammatory cytokines, thus achieving satisfactory prevention and treatment in neuroprotective therapy. This study also sheds light on the neuroprotective action mechanisms of ZIF-8capped nanomedicine against reperfusion-induced injury in ischemic stroke.

This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial license, which permits use, distribution, and reproduction in any medium, so long as the resultant use is not for commercial advantage and provided the original work is properly cited.

Read more:
Highly bioactive zeolitic imidazolate framework-8capped nanotherapeutics for efficient reversal of reperfusion-induced injury in ischemic stroke -...

PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Regulatory News:

NANOBIOTIX (Paris:NANO) (Euronext : NANO ISIN: FR0011341205 the Company), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced its audited consolidated results for the fiscal year ending December 31, 2019:

2019 was a major year for Nanobiotix. We made significant progress in our clinical development plan and are proud to have received our first market approval in Europe for NBTXR3, under the brand name Hensify, in soft tissue sarcoma of the extremity and trunk wall. R&D expenses reflect the strength of our development plan and some key positions have been hired to sustain the activity. In 2020, we are prioritizing the registration pathway for head and neck cancer in the US and Europe, while also continuing our Immuno-Oncology program and evaluating NBTXR3 in other indications with our partners. Philippe Mauberna, Chief Financial Officer of Nanobiotix

The audited consolidated financial statements for the fiscal year ending December 31, 2019 have been approved by the Companys executive board and reviewed by the supervisory board on March 17, 2020.

Consolidated Income Statement: 1

In K

2019

2018

Total revenue and other income

2,541

3,479

Sales

68

116

Service

40

109

Other sales

28

7

Licenses

-

-

Other revenues

2,473

3,363

Research Tax Credit

2,437

3,251

Subsidies

20

90

Other

17

22

Research & Development (R&D) costs

(30,411)

(20,893)

Selling, General and Administrative (SG&A) costs

(18,909)

(12,653)

Operating loss

(46,779)

(30,067)

Financial loss

(4,133)

(277)

Income tax

(3)

-

Net loss for the period

(50,915)

(30,345)

Financial Review

Total Revenue in 2019 amounted to 2.5M vs. 3.5M in 2018, mainly due to:

Total Operating expenses reached 49.3M in 2019 vs. 33.5M in 2018:

Total consolidated headcount reached 110 as of December 31, 2019 vs. 102 as of December 31, 2018, in line with the Companys growth.

Net loss after tax amounted to 50.9M for the year ending December 31, 2019 (vs. 30.3M loss in 2018).

Cash available as of December 31, 2019 amounted to 35.1M (excluding the amount related to the 2018 research tax credit, which was received in February 2020)

Nanobiotix activities and achievements in 2019

Clinical

First ever radioenhancer to receive European market approval

In April 2019, the Company announced that Hensify received European market approval enabling commercialization in 27 European Union countries for the treatment of locally advanced soft tissue sarcoma (STS). Hensify is the brand name for NBTXR3 as approved for the treatment of locally advanced STS.

In July 2019, results from the randomized Phase II/III trial evaluating NBTXR3 in patients with locally advanced STS were published in The Lancet Oncology. The data from the registration study (Act.In.Sarc) demonstrated a significant advantage in both pathological complete response (pCR) and rate of margin-negative resection (R0) for those treated with NBTXR3 activated by radiation therapy (RT) versus RT alone. Data showed that an increase in efficacy was achieved with the addition of NBTXR3, without a significant difference in the safety profile compared to RT alone.

NBTXR3 may present as a valuable option for patients with hepatocellular carcinoma or liver metastasis

During an oral presentation at the ASTRO 2019 annual meeting, Nanobiotix announced phase I results in liver cancer. The study showed promising signs of efficacy for hepatocellular carcinoma (HCC) patients, as every evaluable patient responded and over half (62.5%) reached complete response. Moreover, given that the safety profile was very good, a 5th dose escalation level has been added to the trial.

Clinical collaboration(s)

MD Anderson

In January 2019, the Company announced a clinical collaboration with MD Anderson. This agreement expanded the clinical development plan for NBTXR3, as the nine MD Anderson-led trials will evaluate the product in new indications and patient populations, and should involve around 340 patients.

Pre-clinical collaboration(s)

MD Anderson and Weill Cornell Medical College

At AACR 2019, Nanobiotix presented pre-clinical data from studies currently being conducted through its collaborations with MD Anderson and the Weill Cornell Medical College, demonstrating the efficacy of treatment combinations including NBTXR3, radiotherapy, and anti-PD-1 immunotherapy in treating resistant pre-clinical in vivo lung cancer models.

In November during SITC 2019, Nanobiotix announced new results from an in vivo pre-clinical study showing the generation of adaptive immune response (turning cold tumors into hot tumors), better local control, increased abscopal effect, and significantly increased survival for NBTXR3 activated by RT and anti-PD-1 in combination versus RT alone in combination with anti-PD-1. Additionally, an in vivo RadScopal model showed superior local control along with significant increases in abscopal effect and survival for treatments combining NBTXR3 activated by RT with anti-PD-1 and anti-CTLA-4 versus all other tested combinations.

Financial Events

Registered public offering in the United States

Nanobiotix announced that it planned to conduct a registered public offering of ordinary shares, including in the form of American Depositary Shares (ADSs) in the United States, and has confidentially submitted a draft registration statement on Form F-1 to the U.S. Securities and Exchange Commission.2

View post:
NANOBIOTIX 2019 Annual Results - Business Wire

Researchers at the University of Arizona are developing wearable technology to analyze sweat, which may remove the need to draw blood to learn about the bodys functions in multiple situations.

The project is funded by an 18-month, $519,000 grant from the SEMI Nano-Bio Materials Consortium. The project falls at the crossroads of multiple academic fields, including engineering, chemistry and medicine, and has two main goals: develop a patch to reliably collect the sweat, and develop a biochemistry sensor to analyze the sweat.

When physicians take blood samples, the blood is tested for "biomarkers" which are indicators of medical phenomena like disease or infection. Sweat contains its own index of biomarkers, and collecting it presents a unique series of challenges and advantages.

No matter what molecule you measure in sweat, you need to determine how it relates to the physiological status of the individual, says co-investigator Esther Sternberg, who serves as research director for the Andrew Weil Center for Integrative Medicine and UA professor of medicine. In order to measure the status of the immune system without stressing an individual, one needed to get at immune molecules in a different way than drawing blood, because if you draw blood you need to stick a needle in a person, and thats a stressor If youre trying to understand how the stress response affects the immune response, you need to have a noninvasive, unobtrusive way of measuring the status of the immune response.

Sternberg began working with biomarkers in sweat 20 years ago while working at National Institutes of Health. She says one of the reasons she was drawn to the UA was because of interdisciplinary research projects such as this.

Part of understanding biomarkers in sweat involves using a sweat correlation lab where subjects use exercise bikes to have their sweat collected in a controlled environment.

Were able to relate the levels of the different biomarkers to the exact amount of stress that their bodies are experiencing because we correlate them with heart rate, heart rate variability, breathing and other well-standardized methods to accurately measure the activity of the brain and bodys stress response, Sternberg says. Just measuring the molecules is just the tip of the iceberg, you need to correlate them with all these different measures of the status of the physiological stress response in order to understand what they mean and have actionable results.

One of the first hurdles is how to accurately and quickly collect the sweat. According to project principal investigator Erin Ratcliff, a materials science and engineering professor and head of the UA Laboratory for Interface Science of Printable Electronic Materials, the obvious idea to collect sweat would be to make a patch to gather information from multiple pores at once. However, this means waiting for the space between the patch and skin to fill up with sweat, and during that time, the molecules and biomarkers can chemically change, altering important information.

Ratcliff became involved in this project five years ago, and her role is to convert the biomarkers into an electronic signal that devices use. Current wearable technologies, such as a FitBit, measure bodily data like EKG and heart rate, but dont measure the molecules behind the stress responses, such as cortisol or neuropeptide Y.

Part of the project uses a virtual sweat sensing lab which is a computer simulation that allows researchers to input information about biomarkers, printable materials and device architectures to determine what the output of a sensor would be before they ever make it.

The prototypes that will come out of this 18-month project will be laboratory level with the idea that the components will lead to a product stream for a particular company, but were not going to make thousands of them, Ratcliff says.

While Sternberg says measuring sweat has a tremendous and very wide applicability to many different diseases, it will not completely remove the need to draw blood.

Youre getting information from two different compartments of the body; the blood tells you whats going on in the blood and circulatory system, and sweat tells you whats going on in the tissues and peripheral nervous system I believe this will enhance information and give you information that is not present when you only measure molecules in blood, Sternberg says. Ultimately there may be circumstances in which collecting sweat and collecting molecules from sweat will replace the need to measure the molecules in blood, and in other cases to get a full picture of whats happening in the body, you may need to measure sweat, blood, saliva, urine and on and on.

The U.S. Department of Defense measures "technology readiness" throughout nine levels. According to Ratcliff, the team is aiming for the technology to be at level four at the end of this project. Technology Readiness Level Four means that "basic technological components are integrated to establish that they will work together.

This speaks to the importance of academe and industry working together in an unbiased way, together with federal agencies, to solve complex problems which cant be solved only on the academic side or only on the industry side, Sternberg says. This is an interdisciplinary, multi-college collaboration with an engineer of materials science in Erin Ratcliff, a chemist Ray Runyon, and myself a physician When youre talking about cutting-edge, frontier science, that is the way science has to be done.

Go here to read the rest:
UA developing wearable technology to measure sweat 'biomarkers' - Tucson Local Media

The global Nanomedicine market report by HNY Research offers users a detailed overview of the market and all the main factors affecting the market. The study on global Nanomedicine market, offers profound understandings about the Nanomedicine market covering all the essential aspects like revenue growth, supply chain, sales, key players and regions. There is a target set in market that every marketing strategy has to reach. This report on Nanomedicine focusses on different categories that define this market with a systematic approach that addresses the consumer base, researchers and market experts like the stakeholders. It also gives a clear perspective towards the competition and demand and supply chain.

Request a sample of this report @ https://www.orbisresearch.com/contacts/request-sample/4361506

Manufacturer Detail

By Market Players:Combimatrix, Ablynx, Abraxis Bioscience, Celgene, Mallinckrodt, Arrowhead Research, GE Healthcare, Merck, Pfizer, Nanosphere, Epeius Biotechnologies, Cytimmune Sciences, Nanospectra Biosciences

By Application

By TypeQuantum dots, Nanoparticles, Nanoshells, Nanotubes, Nanodevices

The Nanomedicine market report also offers some presentations and illustrations about the market that comprises pie charts, graphs, and charts which presents the percentage of the various strategies implemented by the service providers in the global Nanomedicine market. This report on Nanomedicine has been very well drafted to benefit anyone studying it. There are different marketing strategies that every marketer looks up to in order to ace the competition in the Global market. Some of the primary marketing strategies that is needed for every business to be successful are Passion, Focus, Watching the Data, Communicating the value To Your Customers, Your Understanding of Your Target Market. Every market research report follows a robust methodology to define its market value. By doing so, the Nanomedicine research study by HNY Research offers collection of information and analysis for each facet of the Nanomedicine market such as technology, regional markets, applications, and types.

Browse the complete report @ https://www.orbisresearch.com/reports/index/2020-2025-global-and-regional-nanomedicine-industry-production-sales-and-consumption-status-and-prospects-professional-market-research-report

This study can benefit investors and business owners in many ways. It studies the business models, strategies, growth, innovations and every information about manufacturers that can help make business predictions and fetch good results. Making right business decisions is an undeniable measure that needs to be taken for market growth. Every market has a set of manufacturers, vendors and consumers that define that market and their every move and achievements becomes a subject of studying for market researchers and other stakeholders. One of the most important aspects focused in this study is the regional analysis. Region segmentation of markets helps in detailed analysis of the market in terms of business opportunities, revenue generation potential and future predictions of the market. For Nanomedicine report, the important regions highlighted are North America, South America, Asia, Europe and Middle East. Another important aspect of every market research report by HNY Research is the study of the key players or manufacturers driving the market forward. The process helps to analyze the opponent thoroughly.

Make an enquiry of this report @ https://www.orbisresearch.com/contacts/enquiry-before-buying/4361506

About Us:

Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.

Contact Us:Hector CostelloSenior Manager Client Engagements4144N Central Expressway,Suite 600, Dallas,Texas 75204, U.S.A.Phone No.: USA: +1 (972)-362-8199 | IND: +91 895 659 5155Email ID: [emailprotected]

Here is the original post:
2020-2025 Global and Regional Nanomedicine Industry Production, Sales and Consumption Status and Prospects Professional Market Research Report -...